| BRAND | DAPASUG-GM-2 Tablet |
| USAGE/APPLICATION | Patients with T2D with eCVD or multiple CV risk factors, to reduce the risk of hospitalization for h |
| PACKAGING TYPE | Tab |
| COMPOSITION | Dapagliflozin 10mg + Glimepiride IP 2mg + Metformin Hydrochloride IP 1000mg (As extended release for |
| MARKETED BY | Intralife India PVT LTD |
DAPASUG-GM-2 Tablet is a groundbreaking solution designed for patients with Type 2 Diabetes (T2D) who are at elevated risk of cardiovascular events or have multiple cardiovascular risk factors. Its primary objective is to significantly reduce the risk of hospitalization for heart failure in this patient population.
